DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Indo Us Biotech Limited — Integrated Filing- Financial

NSE 1 hr ago·12 Aug 2026, 10:07 am

Indo US Biotech

Indo Us Biotech Limited has submitted its standalone unaudited financial results for the quarter ended June 30, 2026. The company has filed these documents with the relevant regulatory authorities, marking the standard disclosure of its performance during this period.

This filing is a routine regulatory requirement that provides investors with an official update on the company's standalone financial health. It allows retail investors to track the company's operational progress and financial position without the impact of any associated entities.

Investors should review the filing to understand the company's current performance trends. Monitoring the reported figures will help in assessing the company's trajectory and making informed investment decisions.